Longeveron Q2 2026 Earnings: CEO Stephen Willard Leads Call

Longeveron reported second-quarter 2026 financial results after the market closed on Aug. 12. The company held an earnings call at 4:30 p.m. EDT to discuss the quarter.

Chief Executive Officer Stephen Willard led the call. He was joined by Dr. Joshua Hare, co-founder and chief science officer; Dr. Nataliya Agafonova, chief medical officer; Devin Blass, chief technology officer; and Marie Washburn, chief financial officer.

The company's prepared remarks included forward-looking statements. Longeveron cautioned that actual results could differ from those projections and directed investors to risk factors in its SEC filings.

Longeveron is a clinical-stage biotechnology company developing therapies for aging-related conditions. Its lead programs target hypoplastic left heart syndrome and aging frailty.

Analysts from H.C. Wainwright, ROTH Capital Partners, and Maxim Group participated in the question-and-answer session following the prepared remarks. The full earnings release is available under the Investors section of the Longeveron website.